The short version of Anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-01. Anything still debated is marked as such rather than presented as settled.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
The metabolome refers to the complete set of small-molecule (<1.5 kDa) metabolites (such as metabolic intermediates, hormones and other signaling molecules, and secondary metabolites) to be found within a biological sample, such as a single organism. The word was coined in analogy with transcriptomics and proteomics; like the transcriptome and the proteome, the metabolome is dynamic, changing from second to second. Although the metabolome can be defined readily enough, it is not currently possible to analyse the entire range of metabolites by a single analytical method. In January 2007, scientists at the University of Alberta and the University of Calgary completed the first draft of the human metabolome. The Human Metabolome Database (HMDB) is perhaps the most extensive public metabolomic spectral database to date and is a freely available electronic database (www.hmdb.ca) containing detailed information about small molecule metabolites found in the human body. It is intended to be used for applications in metabolomics, clinical chemistry, biomarker discovery and general education. The database is designed to contain or link three kinds of data:
Finally, Alexander Shulgin has suggested that nutmeg might be a serotonergic psychedelic via conversion of active constituents into psychedelic amphetamines along with toxic effects from other constituents, though this has not been supported. Nutmeg intoxication has also been confused with those of phencyclidine (PCP) and alcohol as well as likened in some respects to that of alcohol. A clinical study of an isolated fraction of nutmeg that appears to have contained a mixture of myristicin, elemicin, and perhaps a small amount of methylisoeugenol was conducted and published in 1961. A dose of 400 mg of the mixture (equivalent to about 40 g whole nutmeg) was given orally. It produced symptoms suggestive of psychoactive effects such as mild stimulation in 6 of 10 individuals and definite psychoactive effects in 4 of 10 individuals, but failed to exactly reproduce the intoxication characteristic of nutmeg. Effects included euphoria, restlessness, weakness, nervousness, tremor, anxiety, tachycardia, gastrointestinal discomfort, nausea, and others. In the same study, it was found that 10 grams nutmeg with the volatile compounds removed produced no psychoactive effects but did cause in some instances undesirable side effects. It has been suggested that there might be a synergy between myristicin and other nutmeg constituents, for instance other individual allylbenzenes. Alternatively, other constituents may be responsible for the psychoactive and hallucinogenic effects instead. Shulgin reported one other constituent, methoxyeugenol, to be inactive at doses of up to 10 mg orally.
Suvorexant is approved for the treatment of insomnia by the United States Food and Drug Administration (FDA) at doses of 5 to 20 mg and by the Australian Therapeutic Goods Administration (TGA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) at doses of 15 mg (in the elderly) and 20 mg (in younger adults). In the United States, the recommended starting dose is 10 mg and the maximum recommended dose is 20 mg. Higher doses of 30 and 40 mg were also submitted to regulatory agencies for approval but were not authorized due to lack of clearly superior efficacy to doses of 15 to 20 mg and concerns about next-day effects and associated impairment (e.g., driving). In addition to the preceding doses, suvorexant has been assessed at higher doses of up to 100 mg in clinical trials. These higher doses appeared to be more effective at promoting sleep than lower doses but produced greater next-day effects. Lower approved doses of suvorexant in the United States in the range of 5 to 10 mg were not extensively evaluated in clinical trials. The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommend the use of suvorexant in the treatment of sleep-onset and sleep-maintenance insomnia along with various other sleep medications. Orexin receptor antagonists are not used as first-line treatments for insomnia due to their costs and concerns about possible misuse liability. Generic formulations of orexin receptor antagonists including suvorexant are not yet available.
The superficial layer of transitional epithelium is connected to the basal layer via cellular projections, such as intermediate filaments protruding from the cellular membrane. These structural elements cause the epithelium to allow distension; however, these also cause the tissue to be relatively fragile and, therefore, difficult to study.
After the great success in the United States, the incandescent light bulb patented by Edison also began to gain widespread popularity in Europe; among other places, the first Edison light bulbs in the Nordic countries were installed at the weaving hall of the Finlayson's textile factory in Tampere, Finland in March 1882. On 4 March 1880, just five months after Edison's light bulb, Alessandro Cruto developed a process to create thin carbon filaments by heating thin platinum filaments in the presence of gaseous ethyl alcohol to coat them with pure graphite, and then sublimating the platinum at high temperatures. In 1882 at the Munich Electrical Exhibition in Bavaria, Germany Cruto demonstrated bulbs that were more efficient than Edison's and produced a better, whiter light. Lewis Latimer, employed at the time by the United States Electric Lighting Company, developed an improved method of heat-treating carbon filaments which reduced breakage and allowed them to be molded into novel shapes, such as the characteristic "M" shape of Maxim filaments. On 17 January 1882, Latimer received a patent for the "Process of Manufacturing Carbons", an improved method for the production of light bulb filaments, which was purchased by the United States Electric Light Company. Latimer patented other improvements such as a better way of attaching filaments to their wire supports. In Britain, the Edison and Swan companies merged into the Edison and Swan United Electric Company (later known as Ediswan, and ultimately incorporated into Thorn Lighting Limited).
Sources: en.wikipedia.org
=== Newborn === Newborns of mammals are exceptional in protein digestion and assimilation in that they can absorb intact proteins at the small intestine. This enables passive immunity, i.e., transfer of immunoglobulins from the mother to the newborn, via milk.
Conservation of mass Conservation of energy Conservation of momentum The continuum assumption For example, the assumption that mass is conserved means that for any fixed control volume (for example, a spherical volume)—enclosed by a control surface—the rate of change of the mass contained in that volume is equal to the rate at which mass is passing through the surface from outside to inside, minus the rate at which mass is passing from inside to outside. This can be expressed as an equation in integral form over the control volume.
On 28 September 2010, former captain James Hird was named as Essendon's new coach from 2011 on a four-year deal. Former Geelong dual premiership-winning coach and Essendon triple-premiership winning player Mark Thompson later joined the coaching panel. Thompson introduced Essendon to performance coach Dean Robinson, with whom he had worked at Geelong; and, at Robinson's suggestion, they were introduced to sports scientist Stephen Dank. The club believed that it was lagging the rest of the competition in its supplements, particularly to aid player recovery. Subsequently, the club hired Robinson as high-performance coach in September 2011 and hired Dank as a sports scientist in November 2011. Dank was given primary responsibility to establish and run the supplements program. The program primarily comprised subcutaneous injections of supplements to improve soft tissue recovery times, to enable players to endure and benefit from a heavier training workload. The players signed consent forms for the program and were assured that all substances were ASADA-approved. The program included injections of AOD-9604, colostrum, Tribulus and an unspecified variety of thymosin supplement which was described on forms only as "thymosin" – which the Court of Arbitration for Sport (CAS) would later conclude was the banned, performance-enhancing thymosin beta-4 variety. The program also included supplements in pill form and intravenous vitamin drips.
==== Service to the Allies during World War II ==== Jung was in contact with Allen Dulles of the Office of Strategic Services (predecessor of the Central Intelligence Agency) and provided valuable intelligence on the psychological condition of Hitler. Dulles referred to Jung as "Agent 488" and offered the following description of his service: "Nobody will probably ever know how much Professor Jung contributed to the Allied Cause during the war, by seeing people who were connected somehow with the other side". Jung's service to the Allied cause through the OSS remained classified after the war.
The three substrates of this enzyme are benzaldehyde, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are benzoic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is benzaldehyde:NADP+ oxidoreductase. Other names in common use include NADP+-linked benzaldehyde dehydrogenase, and benzaldehyde dehydrogenase (NADP+). This enzyme participates in benzoate degradation via hydroxylation and toluene and xylene degradation.
Sources: en.wikipedia.org
The Bjelke-Petersen Ministry was a ministry of the Government of Queensland and was led by Premier Joh Bjelke-Petersen, who led the Country Party and its successor, the National Party. It succeeded the Chalk Ministry on 8 August 1968 as part of a series of events following the death of former Premier Jack Pizzey on 31 July. It was succeeded by the Ahern Ministry on 1 December 1987 following Bjelke-Petersen's resignation as Premier. All lists below are ordered by decreasing seniority within the Cabinet, as indicated by the Government Gazette and the Hansard index. Blue entries indicate members of the Liberal Party, while non-shaded entries indicate members of the Country or National Party.
== Flexible design == The functional group, the spacer and the lipid tail components of the FSL Kode construct can each be individually designed resulting in FSL Kode constructs with specific biological functions. The functional head group is usually the bioactive component of the construct and the various spacers and lipids influence and effect its presentation, orientation and location on a surface. Critical to the definition of an FSL Kode construct is the requirement to be dispersible in water, and spontaneously and stably incorporate into cell membranes. Other lipid bioconjugates that include components similar to FSLs but do not have these features are not termed as Function-Spacer-Lipid Kode constructs.
=== In other animals === Lingual lipase – Rats and mice secrete a type of lipase (fat-digesting enzyme) from the Von Ebner's glands which are located at the back of the tongue. The analogous enzyme in humans is secreted in the stomach and called gastric lipase (LIPF).
Acta Biochimica et Biophysica Sinica was a Chinese-language journal entitled "Shengwu Huaxue Yu Shengwu Wuli Xuebao" (see box below), which began publishing sometime in 1958 or 1959, or August 1961, until December 2003 (depending on the source). Tables of contents were in English. Summaries (abstracts) were in English and Russian, and text of articles in Chinese. Later issues were promulgated in the Chinese and English languages. The translated title was "Journal of Biochemistry and Biophysics". The frequency was quarterly from 1959 to 1963, bimonthly from 1964 to 2002, and finally, monthly by 2003. Publication was suspended from 1966 to 1975. It was indexed in Chemical Abstracts Service. It may have published 35 volumes in total, over the years. In 2004 the journal switched to a full English-language journal under its current title. Official website Institute of Biochemistry and Cell Biology Archived 2003-12-17 at the Wayback Machine, SIBS, CAS
BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California. It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. In July 2021, BioLegend was acquired by PerkinElmer for $5.25 billion and now operates as Revvity. BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, proteogenomics, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.